EPRX Stock Overview A clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Eupraxia Pharmaceuticals Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Eupraxia Pharmaceuticals Historical stock prices Current Share Price CA$4.33 52 Week High CA$7.64 52 Week Low CA$3.07 Beta 1.56 1 Month Change -13.92% 3 Month Change 12.47% 1 Year Change -21.27% 3 Year Change 94.17% 5 Year Change n/a Change since IPO -37.25%
Recent News & Updates
Eupraxia Pharmaceuticals Inc. Diffusphere Technology Demonstrates Targeted Drug Release While Minimizing Systemic Exposure for A Period of More Than Six Months Nov 20 Eupraxia Pharmaceuticals Inc. announced that it has received CAD 44.52819 million in funding Nov 01
Eupraxia Pharmaceuticals Inc. Appoints Amanda Malone as Chief Operating and Rahul Sarugaser, as Executive Vice President of Corporate Development Oct 05
Price target decreased by 13% to CA$13.75 Sep 11
Eupraxia Pharmaceuticals Announces Data from Resolve Phase 1B/2A Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Sep 11
New major risk - Financial position Aug 14 See more updates
Eupraxia Pharmaceuticals Inc. Diffusphere Technology Demonstrates Targeted Drug Release While Minimizing Systemic Exposure for A Period of More Than Six Months Nov 20 Eupraxia Pharmaceuticals Inc. announced that it has received CAD 44.52819 million in funding Nov 01
Eupraxia Pharmaceuticals Inc. Appoints Amanda Malone as Chief Operating and Rahul Sarugaser, as Executive Vice President of Corporate Development Oct 05
Price target decreased by 13% to CA$13.75 Sep 11
Eupraxia Pharmaceuticals Announces Data from Resolve Phase 1B/2A Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Sep 11
New major risk - Financial position Aug 14
Health Check: How Prudently Does Eupraxia Pharmaceuticals (TSE:EPRX) Use Debt? Jul 30
Independent Director recently bought CA$52k worth of stock Jul 04
Eupraxia Pharmaceuticals Announces Data from the Phase 1b/2a RESOLVE Clinical Trial May 25
New minor risk - Market cap size Apr 10
Eupraxia Pharmaceuticals Inc., Annual General Meeting, Jun 06, 2024 Apr 09
Insufficient new directors Apr 01
Price target decreased by 7.4% to CA$15.75 Mar 19 Eupraxia Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of CAD 30 million. Eupraxia Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of CAD 30 million.
Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IAR Feb 03
Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the Knee Jan 30
Price target increased by 12% to CA$16.50 Jan 28
Eupraxia Pharmaceuticals Inc. Announces Positive Clinical Data in EP-104GI RESOLVE Trial Dec 13
Eupraxia Pharmaceuticals Inc. Announces Updates for Its Two Clinical Programs, EP-104IAR and EP-104GI Dec 11
New minor risk - Market cap size Nov 01
Eupraxia Pharmaceuticals Inc. Announces Initiation of Second Cohort in Phase 1B/2A Clinical Trial in Eosinophilic Esophagitis Oct 12
Price target decreased by 20% to CA$14.75 Aug 25 Eupraxia Pharmaceuticals Inc. announced that it expects to receive CAD 21.999999 million in funding Aug 05
New minor risk - Shareholder dilution Aug 02
Eupraxia Pharmaceuticals Reports Positive Topline Data in Its Phase 2B Osteoarthritis Trial with Ep-104IAR Jun 27
Eupraxia Pharmaceuticals Receives U.S. FDA Fast Track Designation for Ep-104Iar in Treatment of Osteoarthritis Jun 14
Eupraxia Pharmaceuticals Inc. Doses First Patient in Phase 1B/2A Eosinophilic Esophagitis Trial Jun 09
Eupraxia Pharmaceuticals Inc. Appoints Mark Kowalski as Chief Medical Officer May 19
Price target increased to CA$8.35 Jan 11
Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee Osteoarthritis Dec 08
Eupraxia Pharmaceuticals Appoints Paul Brennan to Chief Business Officer Nov 02
Eupraxia Pharmaceuticals Initiates Phase 2 Study in Eosinophilic Esophagitis Oct 13
Eupraxia Pharmaceuticals Provides Update for Phase 2 Study in Knee Osteoarthritis for Lead Drug Candidate EP-104IAR Oct 12
Independent Director recently bought CA$122k worth of stock Jun 11
Price target decreased to CA$6.50 Apr 27
Independent Director recently bought CA$427k worth of stock Apr 27
Independent Director recently bought CA$427k worth of stock Apr 24 Eupraxia Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 13.09335 million. Apr 22
Independent Director recently bought CA$500k worth of stock Apr 16
Eupraxia Pharmaceuticals Inc., Annual General Meeting, Jun 02, 2022 Mar 31
Eupraxia Pharmaceuticals Inc., Annual General Meeting, Jun 02, 2022 Mar 30
Independent Director recently bought CA$78k worth of stock Dec 10
Eupraxia Pharmaceuticals Inc. Provides Update on Its Phase 2 Trial for Osteoarthritis Drug Candidate EP-104IAR Dec 03
Eupraxia Pharmaceuticals Inc. Commences Patient Screening for its Phase 2 Trial for Osteoarthritis Drug Candidate Ep-104IAR Sep 15
CEO & Director recently bought CA$73k worth of stock Aug 26
Eupraxia Pharmaceuticals Inc. Announces Authorization of Clinical Trial Application for Phase 2 Trial of Ep-104Iar in Osteoarthritis of the Knee Jul 20
Director recently bought CA$200k worth of stock Mar 16
Eupraxia Pharmaceuticals Inc. has completed an IPO in the amount of CAD 41 million. Mar 11 Shareholder Returns EPRX CA Biotechs CA Market 7D -10.7% -1.8% -3.7% 1Y -21.3% 15.3% 15.0%
See full shareholder returns
Return vs Market: EPRX underperformed the Canadian Market which returned 15% over the past year.
Price Volatility Is EPRX's price volatile compared to industry and market? EPRX volatility EPRX Average Weekly Movement 11.5% Biotechs Industry Average Movement 12.9% Market Average Movement 8.2% 10% most volatile stocks in CA Market 17.6% 10% least volatile stocks in CA Market 2.9%
Stable Share Price: EPRX has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: EPRX's weekly volatility (12%) has been stable over the past year.
About the Company Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company’s lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology.
Show more Eupraxia Pharmaceuticals Inc. Fundamentals Summary How do Eupraxia Pharmaceuticals's earnings and revenue compare to its market cap? EPRX fundamental statistics Market cap CA$156.38m Earnings (TTM ) -CA$40.55m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) EPRX income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$28.22m Earnings -US$28.22m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 23:42 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Eupraxia Pharmaceuticals Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Tania Armstrong-Whitworth Canaccord Genuity Gary Nachman Raymond James & Associates Rahul Sarugaser Raymond James Ltd.
Show 2 more analysts 
